Last, insulin Icodec works better when used in a basal regimen only rather than in the context of a basal-bolus regimen, resulting in a greater ETD in HbA1c (−0.22%), with a higher chance of achieving HbA1c < 7% (+33%) and HbA1c < 7% without clinically relevant or severe hypoglycemia (+28%), and a higher TIR (around 65 min/day) and lower TAR (−74 min/day) compared to once-daily basal analogs. The gene discussed is INS; the disease is Hypoglycemia.